Ditchcarbon
  • Customers
  1. Organizations
  2. Abacus Medicine
Public Profile
Pharmaceutical Preparation Manufacturing
DK
updated a day ago

Abacus Medicine

Company website

Abacus Medicine, a leading player in the pharmaceutical industry, is headquartered in Denmark (DK) and operates extensively across Europe. Founded in 2004, the company has established itself as a key provider of parallel-imported medicines, ensuring access to high-quality pharmaceuticals at competitive prices. Abacus Medicine's core services include sourcing, distributing, and supplying a wide range of prescription medications, with a focus on efficiency and compliance with regulatory standards. The company is renowned for its commitment to quality assurance and has achieved significant milestones, including partnerships with major healthcare providers. With a strong market position, Abacus Medicine continues to innovate in the pharmaceutical supply chain, making it a trusted name in the industry. Its unique approach to parallel imports not only enhances accessibility but also contributes to cost savings for healthcare systems across its operational regions.

DitchCarbon Score

How does Abacus Medicine's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

32

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Abacus Medicine's score of 32 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

58%

Let us know if this data was useful to you

Abacus Medicine's reported carbon emissions

In 2024, Abacus Medicine, headquartered in Denmark (DK), reported total carbon emissions of approximately 553,400 kg CO2e, comprising 235,300 kg CO2e from Scope 1 and 318,100 kg CO2e from Scope 2 (market-based). This marks a slight increase from 2023, where emissions were about 632,900 kg CO2e (Scope 2, market-based) and 216,900 kg CO2e (Scope 1). Over the past few years, Abacus Medicine has shown fluctuations in its emissions, with 2022 figures indicating approximately 601,300 kg CO2e (Scope 2, market-based) and 213,700 kg CO2e (Scope 1). The company has not disclosed any Scope 3 emissions data, which typically includes indirect emissions from the supply chain and product use. Despite the lack of specific reduction targets or initiatives, Abacus Medicine is a current subsidiary of Abacus Medicine A/S, inheriting its emissions data and sustainability commitments. The company has not set any Science-Based Targets Initiative (SBTi) reduction targets or made specific climate pledges, indicating a potential area for future development in their climate strategy. Overall, while Abacus Medicine has made strides in tracking its emissions, the absence of clear reduction commitments suggests an opportunity for enhanced climate action in alignment with industry standards.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2018201920202021202220232024
Scope 1
62,600
000,000
000,000
000,000
000,000
000,000
000,000
Scope 2
-
-
-
000,000
000,000
000,000
000,000
Scope 3
-
-
-
-
-
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Abacus Medicine's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Abacus Medicine is in DK, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Abacus Medicine is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 11 hours ago

HAEMATO AG

DE
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Concord Biotech

IN
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Alium Medical Ltd

GB
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Cencora

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250829.1
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy